Update: Siponimod (Mayzent) for Secondary Progressive MS
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the Neurological Advisory Committee regarding appropriate Special Authority criteria. PTAC’s recommendation noted specifically the consideration of […]
My aHSCT story – Celia Attwood
My name is Celia Attwood, I’m 32 years old and a mum of 2 beautiful boys. I had been to see my G.P numerous times over the years before being diagnosed with MS but with no definite answers and symptoms always going away I had just got on with life. But I knew something […]